Previous 10 | Next 10 |
-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002’s Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy- -Company’s StealthX™ Technology Shows Promise of Exosome-Based Delivery of ASOs- SAN DIEGO, Oct. 10, 2023 (GLOB...
2023-10-04 16:06:31 ET An estimated 250,000-500,000 people experience a %SpinalCordInjury (SCI) annually, with roughly 17,000 new cases in the US and 27,000 in Europe each year, leaving many of those people permanently confined to a wheelchair. What if there were a way to repair the dam...
Toronto, Ontario--(Newsfile Corp. - October 4, 2023) - Caprock Mining Corp. (CSE: CAPR) (" Caprock " or the " Company ") is pleased to announce that it has filed on SEDAR+ the National Instrument 43-101 ("NI 43-101") Technical Report (the " Technical Report ") for its recently optioned Ackley Lit...
2023-09-29 09:36:50 ET More on Capricor Capricor: Q4 2023 Interim Analysis For DMD Treatment Makes This A Must Watch Capricor Therapeutics, Inc. (CAPR) Q2 2023 Earnings Call Transcript Capricor Therapeutics slumps 25%, prices $23M equity Seeking Alpha’...
2023-09-29 09:06:05 ET More on Capricor Therapeutics Capricor: Q4 2023 Interim Analysis For DMD Treatment Makes This A Must Watch Seeking Alpha’s Quant Rating on Capricor Therapeutics Historical earnings data for Capricor Therapeutics For further detai...
SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that it has ...
-FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002’s Path Towards a Biologics License Application (BLA)- -Company On Track to Complete HOPE-3 Enrollment and Report Outcome from Interim Analysis in Q4 2023- -Conference Call and Webcast T...
Toronto, Ontario--(Newsfile Corp. - September 20, 2023) - Caprock Mining Corp. (CSE: CAPR) (" Caprock " or the " Company ") is pleased to announce high-grade lithium assay results from samples obtained during a recently concluded prospecting and sampling program on the eastern-most claim block (t...
Toronto, Ontario--(Newsfile Corp. - September 11, 2023) - Caprock Mining Corp. (CSE: CAPR) (" Caprock " or the " Company ") is pleased to announce that its technical team has discovered the presence of zinnwaldite, an extraordinary lithium-bearing mineral, during a recently concluded prospecting ...
SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the...
News, Short Squeeze, Breakout and More Instantly...
Capricor Therapeutics Inc. Company Name:
CAPR Stock Symbol:
NASDAQ Market:
Capricor Therapeutics Inc. Website:
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000 ® Index an...
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating Stabilization of Cardiac Function Over 3 Years of Treatment- -Pre-BLA Meeting with FDA...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor Therapeutics, please note that the words "Pre-BLA Meeting with FDA for Deramiocel" were omitted ...